Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial
Menée aux Etats-Unis auprès de 149 977 participants de l'essai "Prostate, Lung Colorectal and Ovarian Cancer Screening Trial" dont 74 366 témoins (âge : 55-74 ans), cette étude évalue l'association entre un apport en calcium et la carcinogenèse colorectale, puis analyse l'effet du rapport calcium/magnésium sur cette association
Résumé en anglais
Background : We aimed to evaluate the associations between calcium and various stages of colorectal carcinogenesis and whether these associations are modified by the calcium to magnesium (Ca:Mg) ratio.
Methods : We tested our hypotheses in the prostate lung, colorectal and ovarian cancer screening trial.
Results : Calcium intake did not show a dose–response association with incident adenoma of any size/stage (P-trend = 0.17), but followed an inverse trend when restricted to synchronous/advanced adenoma cases (P-trend = 0.05). This inverse trend was mainly in participants with Ca:Mg ratios between 1.7 and 2.5 (P-trend = 0.05). No significant associations were observed for metachronous adenoma. Calcium intake was inversely associated with CRC (P-trend = 0.03); the association was primarily present for distal CRC (P-trend = 0.01). The inverse association between calcium and distal CRC was further modified by the Ca:Mg ratio (P-interaction < 0.01); significant dose–response associations were found only in participants with a Ca:Mg ratio between 1.7 and 2.5 (P-trend = 0.04). No associations for calcium were found in the Ca:Mg ratio above 2.5 or below 1.7.
Conclusion : Higher calcium intake may be related to reduced risks of incident advanced and/or synchronous adenoma and incident distal CRC among subjects with Ca:Mg intake ratios between 1.7 and 2.5.
